Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
4 years i wait
Time prépare Vegas party!!!
When is the Vegas party?
Very important i tink big News long and strong
I want buy more you tink go up Quick tomorrow
VEGAS PARTY??soon
For the list i take 20000 more
I Buy 20000 fnma now my position 40000
Is it Time to go All in on fannie?
I already have 20000 @3
I buy today for me same story Starbucks
Tanks i buy ifon now
Time to buy?
I sell 5000 4,67 for take mcur
Vnrx go to the moon
Long and stong i Want go Vegas 20000 price3.12!
Today open 3$ ?
Tank for the New i keep vnrs for 2 years this Time i buy friday CHMA look (sorry for my anglais i m french)
I keep my position for 3 years but i buy cytn ctix chma and nwbo
Hello no News?
Good to see you 20000 actions 3,12$ long and strong
Nouvelle hausse des cas en Guinée et Sierra Leone
1/251 - 10.06 Le nombre de nouveaux cas de virus Ebola a progressé en Guinée et en Sierra Leone pour la deuxième semaine consécutive, a annoncé mercredi l'Organisation mondiale de la santé (OMS).
(Photo: Kenzo Tribouillard)
Le nombre de nouveaux cas de virus Ebola a progressé en Guinée et en Sierra Leone pour la deuxième semaine consécutive, a annoncé mercredi l'Organisation mondiale de la santé (OMS).
Durant la première semaine de juin, il y a eu 16 nouveaux cas en Guinée alors qu'en Sierra Leone, il y a eu 15 nouveaux cas. Pendant la dernière semaine de mai, il y avait eu 13 nouveaux cas en Guinée, contre 9 la semaine précédente. En Sierra Leone il y a eu 12 nouveaux cas, contre 3 la semaine précédente.
Cet article est-il intéressant?
3
4
1
Non seulement les cas ont augmenté, mais les zones géographiques concernées se sont étendues en Guinée, touchant notamment de nouveau Conakry, la capitale. La maladie est aussi réapparue dans le district de Kindia (à l'est de Conakry).
Il y a eu 869 travailleurs de santé touchés par le virus en Sierra Leone, en Guinée et au Liberia, dont 507 sont morts, depuis le début de l'épidémie il y a 18 mois, ajoute l'OMS. Au total, l'organisation a recensé 27'237 cas d'Ebola, dont 11'158 décès. L'épidémie a touché essentiellement la Guinée, la Sierra Leone et le Liberia, officiellement débarrassé du virus depuis le 9 mai dernier. (ats)
10.06.2015, 20:46
Plus de vidéos
I play long term good article in belgium about them
Vnrx go ??
Why FXCM not Green ??
NYSEMKT:ONVO) saw its shares rally more than 28% in April. The gains were driven partly by the company's announcement of preliminary financial information for the fourth quarter and fiscal year ended March 31, 2015. During the fiscal year ended March 31, 2015, ONVO launched its liver toxicity product and service. ONVO noted that the results for fiscal 2015 mainly reflect the initial uptake of its pre-launch product and service. While the revenue generated by ONVO in fiscal 2015 was just $571,000, the initial uptake is encouraging. However, for significant revenue growth, ONVO will require greater adoption of its product and services.
ONVO is focused on the development and commercialization of functional tissues, which can be utilized in drug discovery and development, biological research, and as therapeutic implants. ONVO uses its platform technology to create human tissue constructs in 3D. In November 2014, ONVO launched its liver toxicity product, which is part of the exVive3D™ portfolio offering. The company expects to launch exVive3D™ Human Kidney Tissue in the second half of calendar year of 2016.
Pharmaceutical and biotechnology companies spend billions of dollars in developing drugs. However, only a small percentage of experimental drugs get to the commercial stage, resulting in significant sunk costs. On several occasions, the failure of a trial is due to safety issues, specifically toxicity issues. This is where ONVO's technology comes in. The toxicity of a drug is only found out in human clinical trials, which means that particular drug has already reached advanced clinical trial stages and the company has already spent billions in research and development. ONVO's technology has the potential to save pharma and biotech companies billions of dollars.
ONVO's technology can help drug developers in identifying toxicity issues early on in the clinical trial stages. This is because ONVO's 3D tissues are human and reproduce many aspects of in vitro tissue architecture and function. As a result, they offer an advantage over non-human animal models with respect to prediction of in vivo human outcomes.
There is no doubt that the toxicity products have tremendous potential. ONVO believes that its liver toxicity product and service alone has potential of generating more than $100 million in revenue. In a presentation last year, ONVO noted that the combined value of the total addressable market for liver and kidney toxicology products is around $3.4 billion. However, the main issue is adaptability.
ONVO's success depends on whether drug developers adapt its toxicity products. These products can save pharma and biotech companies billions of dollars in research and development expenses but there is also a risk for them. At this stage, there is not sufficient data to confirm the accuracy of ONVO's toxicity products' prediction. And without this data, it is difficult to predict the adaptability of ONVO's products.
In fiscal 2015, ONVO generated $571,000 in revenue and burned $21.1 million. Although the company had $50.1 million in cash on its balance sheet at the end of fiscal 2015, its annual burn rate is expected to be $25 million in the current fiscal year. This means that ONVO will see some dilution in the medium-term. While dilution risk is understandable for a development stage company, my concern is that if ONVO's toxicity products do not see greater adoption in the medium-term, the company will continue to burn a lot of cash. I believe this is the reason why ONVO shares have been trading more than 50% below the levels they traded in early 2014. As of April 30, 2015, nearly 27% of ONVO shares were shorted. It must be noted though that the short ratio was quite high at nearly 9 days. This means that any positive news can result in a short squeeze. This possibly explains the 28% surge in April as well.
Of course, the toxicology products are just one part of the ONVO story. The other major and perhaps bigger opportunity for the company is in printing organs for transplants. But this is a long-term opportunity and to an extent relies on the success of toxicity products and services.
I believe that there is far too much uncertainty with ONVO at this stage. While there is tremendous potential in the company's product offerings, a lot will depend on the uptake of its liver and kidney toxicity products. The initial uptake has been encouraging but more evidence is needed before the product can be deemed a success. The success of the toxicity products is crucial for ONVO as it will enable the company to capitalize on long-term opportunity in transplants. Given the high short interest and high short ratio, ONVO shares could see some short period of strong gains on the back of some positive development but long-term investors should only look at this stock when there is evidence of greater adoption of toxicity products.
Disclosure: The author has no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.
The author wrote this article themselves, and it expresses their own opinions. The author is not receiving compensation for it (other than from Seeking Alpha). The author has no business relationship with any company whose stock is mentioned in this article.
Hello roman tank for information my position 10000 Vnrx 4,12 you tink résultat good
here long and strong volition great future for revolutionize screening for cancers
Znapp utilser a geneve suisse
I tink 14 novembre
But i live geneve suisse and you action préfère for the moment
I french sorry for my language you play ifon fnma rax ibio
I have only 1000 actions i play long 2015 robot pepper ??
ok I sell and buy a $ 1.50
Big green or red ?
Today green or red ?
I don t think ibio break 1$ big manipulation in 2 week 2,5$
SoftBank Corp's human-like robot named "Pepper" is displayed at its branch, as pedestrians peer at it through a glass window, in Tokyo, in this June 6, 2014 file photo. Nestle SA will enlist a thousand humanoid robots to help sell its coffee makers at electronics stores across Japan, becoming the first corporate customer for the chatty, bug-eyed androids unveiled in June by tech conglomerate SoftBank Corp. The waist-high robot was touted by Japan's SoftBank as capable of learning and expressing human emotions, and of serving as a companion or guide in a country that faces chronic labour shortages. Nestle said on October 29, 2014 it would initially commission 20 of the robots, called Pepper, in December to interact with customers and promote its coffee machines. By the end of next year, the maker of Nescafe coffee and KitKat chocolate bars plans to have the robots working at 1,000 stores. REUTERS/Yuya Shino/Files (JAPAN - Tags: SCIENCE TECHNOLOGY BUSINESS SOCIETY)
IMPORTANT QUESTION: if in ibio there is a big contract coming soon, then why is the share price only 1.5?